The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma
Fat mass and obesity-associated (FTO) protein, the first m6A demethylase identified in 2011, regulates multiple aspects of RNA biology including splicing, localization, stability, and translation. Accumulating data show that FTO is involved in numerous physiological processes and is implicated in mu...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-11-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523322001772 |
| _version_ | 1828432362312040448 |
|---|---|
| author | Dalin Zhang Sarah Wornow Donna M. Peehl Erinn B. Rankin James D. Brooks |
| author_facet | Dalin Zhang Sarah Wornow Donna M. Peehl Erinn B. Rankin James D. Brooks |
| author_sort | Dalin Zhang |
| collection | DOAJ |
| description | Fat mass and obesity-associated (FTO) protein, the first m6A demethylase identified in 2011, regulates multiple aspects of RNA biology including splicing, localization, stability, and translation. Accumulating data show that FTO is involved in numerous physiological processes and is implicated in multiple cancers including renal cell carcinoma (RCC). However, the exact role of FTO in RCC remains controversial. Some studies demonstrated that decreased FTO expression was associated with aggressive clinical features and shorter overall survival in clear cell RCC (ccRCC) patients, while others found that FTO inhibition selectively reduced the growth and survival of VHL-deficient ccRCC cells in vitro and in vivo. Here, we review the evidence supporting either a promoting or suppressive role of FTO in kidney cancers, the mechanisms of action of FTO, and recent progress in developing FTO inhibitors. |
| first_indexed | 2024-12-10T18:19:05Z |
| format | Article |
| id | doaj.art-f166a1a4b61f4f16a3618f746bfbde9f |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-10T18:19:05Z |
| publishDate | 2022-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-f166a1a4b61f4f16a3618f746bfbde9f2022-12-22T01:38:16ZengElsevierTranslational Oncology1936-52332022-11-0125101518The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinomaDalin Zhang0Sarah Wornow1Donna M. Peehl2Erinn B. Rankin3James D. Brooks4Department of Urology, School of Medicine, Stanford University, Stanford, CA 94305, USAUndergraduate Student Program, Brown University, Providence, RI, USADepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USADepartment of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA, USADepartment of Urology, School of Medicine, Stanford University, Stanford, CA 94305, USA; Corresponding author.Fat mass and obesity-associated (FTO) protein, the first m6A demethylase identified in 2011, regulates multiple aspects of RNA biology including splicing, localization, stability, and translation. Accumulating data show that FTO is involved in numerous physiological processes and is implicated in multiple cancers including renal cell carcinoma (RCC). However, the exact role of FTO in RCC remains controversial. Some studies demonstrated that decreased FTO expression was associated with aggressive clinical features and shorter overall survival in clear cell RCC (ccRCC) patients, while others found that FTO inhibition selectively reduced the growth and survival of VHL-deficient ccRCC cells in vitro and in vivo. Here, we review the evidence supporting either a promoting or suppressive role of FTO in kidney cancers, the mechanisms of action of FTO, and recent progress in developing FTO inhibitors.http://www.sciencedirect.com/science/article/pii/S1936523322001772m6A RNA demethylaseFTORenal cell carcinomaCancer progressionPrognosisInhibitors |
| spellingShingle | Dalin Zhang Sarah Wornow Donna M. Peehl Erinn B. Rankin James D. Brooks The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma Translational Oncology m6A RNA demethylase FTO Renal cell carcinoma Cancer progression Prognosis Inhibitors |
| title | The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma |
| title_full | The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma |
| title_fullStr | The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma |
| title_full_unstemmed | The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma |
| title_short | The controversial role and therapeutic development of the m6A demethylase FTO in renal cell carcinoma |
| title_sort | controversial role and therapeutic development of the m6a demethylase fto in renal cell carcinoma |
| topic | m6A RNA demethylase FTO Renal cell carcinoma Cancer progression Prognosis Inhibitors |
| url | http://www.sciencedirect.com/science/article/pii/S1936523322001772 |
| work_keys_str_mv | AT dalinzhang thecontroversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT sarahwornow thecontroversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT donnampeehl thecontroversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT erinnbrankin thecontroversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT jamesdbrooks thecontroversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT dalinzhang controversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT sarahwornow controversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT donnampeehl controversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT erinnbrankin controversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma AT jamesdbrooks controversialroleandtherapeuticdevelopmentofthem6ademethylaseftoinrenalcellcarcinoma |